AR095469A1 - Partículas de resinato de fenilefrina y uso de las mismas en formulaciones farmacéuticas, complejo fármaco resina, partícula de liberación prolongada, formulación farmacéutica - Google Patents

Partículas de resinato de fenilefrina y uso de las mismas en formulaciones farmacéuticas, complejo fármaco resina, partícula de liberación prolongada, formulación farmacéutica

Info

Publication number
AR095469A1
AR095469A1 ARP140101072A ARP140101072A AR095469A1 AR 095469 A1 AR095469 A1 AR 095469A1 AR P140101072 A ARP140101072 A AR P140101072A AR P140101072 A ARP140101072 A AR P140101072A AR 095469 A1 AR095469 A1 AR 095469A1
Authority
AR
Argentina
Prior art keywords
phenylefrine
release particle
same
phenylephrine
pharmaceutical formulation
Prior art date
Application number
ARP140101072A
Other languages
English (en)
Original Assignee
Mcneil-Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil-Ppc Inc filed Critical Mcneil-Ppc Inc
Publication of AR095469A1 publication Critical patent/AR095469A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Partículas de fenilefrina adecuadas para formas de dosificación sólidas, semisólidas o líquidas. Reivindicación 1: Un complejo fármaco-resina que comprende fenilefrina y un catión de sulfonato de poliestireno, en donde el catión de sulfonato de poliestireno comprende tamaños de partícula de aproximadamente 74 mm a aproximadamente 177 mm antes de combinarse con la fenilefrina. Reivindicación 2: El complejo fármaco-resina de la reivindicación 1, en donde el catión se selecciona del grupo que consiste en sodio, cobre, cinc, hierro, calcio, estroncio, magnesio y litio. Reivindicación 4: Una partícula de liberación prolongada, en donde la partícula de liberación prolongada comprende el complejo fármaco-resina de la reivindicación 3 recubierto con un recubrimiento. Reivindicación 8: La formulación farmacéutica de la reivindicación 7, que comprende, además, una forma de liberación inmediata de fenilefrina.
ARP140101072A 2013-03-15 2014-03-14 Partículas de resinato de fenilefrina y uso de las mismas en formulaciones farmacéuticas, complejo fármaco resina, partícula de liberación prolongada, formulación farmacéutica AR095469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/832,394 US20140271891A1 (en) 2013-03-15 2013-03-15 Phenylephrine resinate particles and use thereof in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
AR095469A1 true AR095469A1 (es) 2015-10-21

Family

ID=50391378

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101072A AR095469A1 (es) 2013-03-15 2014-03-14 Partículas de resinato de fenilefrina y uso de las mismas en formulaciones farmacéuticas, complejo fármaco resina, partícula de liberación prolongada, formulación farmacéutica

Country Status (16)

Country Link
US (2) US20140271891A1 (es)
EP (1) EP2968224B1 (es)
JP (1) JP6340406B2 (es)
CN (1) CN105377249B (es)
AR (1) AR095469A1 (es)
AU (1) AU2014238058B2 (es)
BR (1) BR112015022925B1 (es)
CA (1) CA2906341A1 (es)
IL (1) IL241036B (es)
MX (1) MX2015012542A (es)
NZ (1) NZ712265A (es)
PH (1) PH12015502029A1 (es)
RU (1) RU2672731C2 (es)
UA (1) UA116011C2 (es)
WO (1) WO2014149525A1 (es)
ZA (1) ZA201507673B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US4221778A (en) 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
CA2269679A1 (en) 1996-12-20 1998-07-02 Warner-Lambert Company Antitussive drugs delivered by partially coated ion exchange resins
US20050112198A1 (en) * 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20070014823A1 (en) * 2005-07-12 2007-01-18 The Procter & Gamble Company Multi phase personal care composition comprising compositions having similar rheology profile in different phases
US7639628B2 (en) 2005-07-14 2009-12-29 University Of Notre Dame Du Lac Response time detection in a network having shared interfaces
BRPI0709606B8 (pt) * 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
EP2029114B1 (en) 2006-06-01 2014-09-24 Merck Sharp & Dohme Corp. Pharmaceutical compositions for sustained release of phenylephrine
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US8394415B2 (en) * 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
BRPI0915411A2 (pt) * 2008-06-26 2015-11-03 Mcneil Ppc Inc partículas revestidas contendo agentes farmaceuticamente ativos
EP2413898A1 (en) * 2009-04-03 2012-02-08 Coating Place, Inc. Modified-release pharmaceutical drug composition
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions

Also Published As

Publication number Publication date
AU2014238058B2 (en) 2018-11-22
CN105377249B (zh) 2019-03-08
JP6340406B2 (ja) 2018-06-06
ZA201507673B (en) 2017-11-29
MX2015012542A (es) 2016-06-30
PH12015502029A1 (en) 2016-01-18
WO2014149525A1 (en) 2014-09-25
EP2968224A1 (en) 2016-01-20
BR112015022925A2 (pt) 2017-07-18
US20210322558A1 (en) 2021-10-21
EP2968224B1 (en) 2020-10-28
CA2906341A1 (en) 2014-09-25
IL241036A0 (en) 2015-11-30
BR112015022925B1 (pt) 2022-10-25
NZ712265A (en) 2020-07-31
RU2672731C2 (ru) 2018-11-19
AU2014238058A1 (en) 2015-09-10
CN105377249A (zh) 2016-03-02
JP2016512249A (ja) 2016-04-25
UA116011C2 (uk) 2018-01-25
IL241036B (en) 2020-01-30
US20140271891A1 (en) 2014-09-18
RU2015144294A (ru) 2017-04-24
BR112015022925A8 (pt) 2022-08-09

Similar Documents

Publication Publication Date Title
ES2536206T3 (es) Parche medicinal
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CY1120507T1 (el) Συνεργιστικη ενισχυση της διανομης νουκλεϊκων οξεων μεσω συμμειγμενων σκευασματων
CR20150629A (es) Compuestos químicos
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
CO6660512A2 (es) Proceso para fabricar composiciones hemostáticas secas y estables
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
AR092497A1 (es) Composicion para formacion de un recubrimiento solido y una union tubular roscada
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
AR093886A1 (es) Antitranspirante / desodorante con polivinilpirrolidona alquilada
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
PE20151051A1 (es) Formulaciones de liberacion modificada para oprozomib
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
SA516371613B1 (ar) Cgrp صيغة قرص لمركبات نشطة تجاه
DOP2014000269A (es) Nueva dosificación y formulación
CL2009001062A1 (es) Mezcla de barniz para revestir una forma farmaceutica de dosificacion solida que comprende a) agua (80 a 99% del peso total), b) un agente formador de pelicula (0,25 a 20% del peso total), y c) un agente de revestimiento (0,01 a 5% del peso total;) proceso de barnizado; forma farmaceutica solida .
AR095469A1 (es) Partículas de resinato de fenilefrina y uso de las mismas en formulaciones farmacéuticas, complejo fármaco resina, partícula de liberación prolongada, formulación farmacéutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure